Cadrenal Therapeutics Inc...
(CVKD)
undefined
undefined%
At close: undefined
11.20
0.00%
After-hours Dec 13, 2024, 04:00 PM EST
Company Description
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company.
The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation.
The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Cadrenal Therapeutics Inc. Common Stock
| Country | United States |
| IPO Date | Jan 20, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Quang X. Pham |
Contact Details
Address: 822 A1A North Ponte Vedra, Florida United States | |
| Website | https://www.cadrenal.com |
Stock Details
| Ticker Symbol | CVKD |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001937993 |
| CUSIP Number | |
| ISIN Number | US1276361086 |
| Employer ID | 88-0860746 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Quang X. Pham | Chairman & Chief Executive Officer |
| Jeffrey Cole | Chief Operating Officer |
| Matthew K. Szot CPA, CPA | Co-Founder & Chief Financial Officer |
| Dr. Douglas W. Losordo FACC, FAHA, M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 25, 2024 | 424B3 | Filing |
| Nov 14, 2024 | S-3 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | D | Filing |
| Nov 07, 2024 | 10-Q | Quarterly Report |
| Nov 07, 2024 | 8-K | Current Report |
| Nov 04, 2024 | 8-K | Current Report |
| Nov 04, 2024 | 424B5 | Filing |
| Oct 24, 2024 | 8-K | Current Report |
| Oct 04, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |